|Abnormalities of white matter microstructure in unmedicated obsessive-compulsive disorder and changes after medication.|
|Jump to Full Text|
|PMID: 22558258 Owner: NLM Status: MEDLINE|
|BACKGROUND: Abnormalities of myelin integrity have been reported in obsessive-compulsive disorder (OCD) using multi-parameter maps of diffusion tensor imaging (DTI). However, it was still unknown to what degree these abnormalities might be affected by pharmacological treatment.
OBJECTIVE: To investigate whether the abnormalities of white matter microstructure including myelin integrity exist in OCD and whether they are affected by medication.
METHODOLOGY AND PRINCIPAL FINDINGS: Parameter maps of DTI, including fractional anisotropy (FA), axial diffusivity (AD), radial diffusivity (RD) and mean diffusivity (MD), were acquired from 27 unmedicated OCD patients (including 13 drug-naïve individuals) and 23 healthy controls. Voxel-based analysis was then performed to detect regions with significant group difference. We compared the DTI-derived parameters of 15 patients before and after 12-week Selective Serotonin Reuptake Inhibitor (SSRI) therapies. Significant differences of DTI-derived parameters were observed between OCD and healthy groups in multiple structures, mainly within the fronto-striato-thalamo-cortical loop. An increased RD in combination with no change in AD among OCD patients was found in the left medial superior frontal gyrus, temporo-parietal lobe, occipital lobe, striatum, insula and right midbrain. There was no statistical difference in DTI-derived parameters between drug-naive and previously medicated OCD patients. After being medicated, OCD patients showed a reduction in RD of the left striatum and right midbrain, and in MD of the right midbrain.
CONCLUSION: Our preliminary findings suggest that abnormalities of white matter microstructure, particularly in terms of myelin integrity, are primarily located within the fronto-striato-thalamo-cortical circuit of individuals with OCD. Some abnormalities may be partly reversed by SSRI treatment.
|Qing Fan; Xu Yan; Jijun Wang; Ying Chen; Xuemei Wang; Chunbo Li; Ling Tan; Chao You; Tianhong Zhang; Sai Zuo; Dongrong Xu; Kemin Chen; Jodie Marie Finlayson-Burden; Zeping Xiao|
Related Documents :
|2132428 - Polymyositis-dermatomyositis--a 25-year follow-up of 50 patients (analysis of clinical ...
25298618 - The antioxidant profiles, lysosomal and membrane enzymes activity in patients with acut...
1451058 - Malignant transformation in paget disease of bone.
19208478 - Immune-mediated rippling muscle disease with myasthenia gravis: a report of seven patie...
38688 - The relationship between the arterial level of angiotensin-converting enzymes and arter...
10655068 - Mutations in the gene encoding peroxisomal alpha-methylacyl-coa racemase cause adult-on...
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2012-04-27|
|Title: PloS one Volume: 7 ISSN: 1932-6203 ISO Abbreviation: PLoS ONE Publication Date: 2012|
|Created Date: 2012-05-04 Completed Date: 2012-09-13 Revised Date: 2013-06-25|
Medline Journal Info:
|Nlm Unique ID: 101285081 Medline TA: PLoS One Country: United States|
|Languages: eng Pagination: e35889 Citation Subset: IM|
|Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.|
|APA/MLA Format Download EndNote Download BibTex|
Axons / drug effects, pathology
Corpus Striatum / drug effects, pathology*
Diffusion Tensor Imaging
Drug Administration Schedule
Frontal Lobe / drug effects, pathology*
Image Processing, Computer-Assisted
Myelin Sheath / metabolism
Nerve Fibers, Myelinated / drug effects, pathology
Obsessive-Compulsive Disorder / drug therapy, pathology*
Occipital Lobe / drug effects, pathology*
Parietal Lobe / drug effects, pathology*
Serotonin Uptake Inhibitors / administration & dosage*, therapeutic use
|0/Serotonin Uptake Inhibitors|
Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS ONE
Journal ID (publisher-id): plos
Journal ID (pmc): plosone
Publisher: Public Library of Science, San Francisco, USA
Fan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received Day: 16 Month: 8 Year: 2011
Accepted Day: 27 Month: 3 Year: 2012
collection publication date: Year: 2012
Electronic publication date: Day: 27 Month: 4 Year: 2012
Volume: 7 Issue: 4
E-location ID: e35889
PubMed Id: 22558258
Publisher Id: PONE-D-11-15900
|Abnormalities of White Matter Microstructure in Unmedicated Obsessive-Compulsive Disorder and Changes after Medication Alternate Title:White Matter in Obsessive-Compulsive Disorder|
|Jodie Marie Finlayson-Burden5|
|Ben J. Harrisonedit1||
1Shanghai Mental Health Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
2Key Laboratory of Brain Functional Genomics, Ministry of Education, Shanghai Key Laboratory of Brain Functional Genomics, Shanghai Key Laboratory of Magnetic Resonance, East China Normal University, Shanghai, China
3Shanghai TCM-Intergrated Hospital, Shanghai, China
4Radiology Department, School of Medicine, Shanghai Jiao Tong University, Ruijin Hospital, Shanghai, China
5Nottingham Institute of Mental Health, University of Nottingham, Nottingham, England
|The University of Melbourne, Australia
|Correspondence: * E-mail: email@example.com (ZX); firstname.lastname@example.org (DX)
Contributed by footnote: Conceived and designed the experiments: ZX CL KC. Performed the experiments: QF JW YC XW LT CY TZ SZ JMFB. Analyzed the data: XY DX. Contributed reagents/materials/analysis tools: QF XY JW YC XW LT YC TZ SZ DX. Wrote the paper: QF XY JW. Revised manuscript critically for important intellectual content: XW YC CL LT CY TZ SZ DX KC JMFB ZX. Approved the final manuscript: QF XY JW YC XW CL LT CY TZ SZ DX KC JMFB ZX.
Obsessive-compulsive disorder (OCD) is one of the most common mental disorders in the general population, with a prevalence rate of 2% to 3% . The main clinical manifestations seen in OCD patients are recurrent, intrusive and distressing thoughts and/or repetitive behaviors, resulting in significantly impaired occupational and social functioning . However, the neurobiological mechanisms of OCD are still unknown.
Previous structural and functional neuroimaging studies have supported the role of fronto-striato-thalamo-cortical circuit impairment in the pathogenesis of OCD. Rotge et al.  found volumetric differences between OCD patients and control subjects in the anterior cingulate cortex, orbitofrontal cortex and thalamus using a meta-analysis. Another meta-analysis, conducted by Whiteside et al.  using results from positron emission tomography (PET) and single photon emission computed tomography (SPECT), proved that significant differences of radiotracer uptake do exist between OCD patients and healthy controls in the orbital frontal cortex and caudate nucleus.
Diffusion tensor imaging (DTI) is a non-invasive method that maps the diffusivity of water molecules in tissue . It is sensitive to the orientation and integrity of the underlying white matter fiber in vivo. Restricted by cell membrane and myelinlayers, the diffusivity perpendicular to fiber direction (radial diffusivity, RD) is lower than that along the length of the fiber (axial diffusivity, AD). Fractional anisotropy (FA) is the most commonly used index to detect this anisotropy, and is considered a sensitive marker of changes in tissue microstructures. Another index, mean diffusivity (MD), measures the average diffusivity in all directions, is frequently used as a complement to FA.
Several DTI studies have investigated white matter abnormalities in OCD patients relative to healthy subjects. These studies have generally supported abnormalities of the fronto-striato-thalamo-cortical loop in the pathogenesis of OCD. Within cortical structures, higher FA and apparent diffusion coefficient (ADC) were observed in the medial frontal region , , and lower FA was found in the parietal lobe , , left lingual gyrus and occipital lobe white matter . In the cingulum, lower FA was reported in the anterior cingulated gyrus , right posterior cingulated gyrus  and cingulated bundle ,while Cannistraro et al.  showed greater FA values in the left cingulum bundle and lower FA values in the right cingulum bundle. Yoo et al.  have reported higher FA in the corpus callosum, while Nakamae et al.  found smaller FA in the anterior body of the corpus callosum. Saito et al.  showed FA reduction in the rostrum of the corpus callosum and Garibotto et al.  also reported lower FA in the splenium of the corpus callosum and altered principal diffusion direction (PDD) along the corpus callosum. Greater FA measures were found in the left anterior limb of internal capsule , white matter around the right caudate  and bilateral semioval center . However, the results of these studies were inconsistent and most of the studies used FA alone as a marker for studying white matter abnormality.
Recent debates have focused upon the interpretation of DTI parameters, suggesting that FA alone is insufficient for characterizing changes in tissue microstructure , . Axial diffusivity and radial diffusivity have been proposed as a more specific markers for axonal and myelin injury, respectively . Increased RD without significant changes in AD was found in the demyelinated mouse brain , . In recent human studies, these parameters were used in combination with FA to investigate white matter microstructure in schizophrenia –, depression  and autism , . These studies found increased RD and insignificant changes in AD, suggesting deficits in myelination. However, a recent report has suggested caution in interpreting changes of the axial and radial diffusivities .
To our knowledge, only one OCD study has employed FA, RD and AD measures . This study found myelin abnormalities represented by increased RD and normal AD in the body of the corpus callosum. However, this study had a cross-sectional design and 10 of the 21 OCD patients were receiving stable doses of drug treatments.
In the current study, we employed the DTI technique to study white matter abnormality in OCD patients using multiple parameters including FA, AD, RD and MD. These parameters were compared for patients before and after 12-week Selective Serotonin Reuptake Inhibitor (SSRI) pharmacotherapy. We hypothesized that abnormalities of white matter microstructure including myelin integrity would be found in OCD patients. We also predicted that sufficient medication would normalize the changes in white matter microstructure.
After the study procedure had been explained to the participants, written informed consent was collected from all participants involved in the study. The research was approved by the local institutional ethics board (Institutional Review Board of Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine).
Twenty-seven patients with OCD and 23 healthy controls participated in the study. All participants were Chinese and right handed, and were generally matched for age, sex and education. The OCD patients were recruited from an outpatient clinic at Shanghai Mental Health Center, Shanghai, China. Inclusion criteria for patients with OCD were as follows: age between 18 and 54; no less than 9 years in education; a DSM-IV diagnosis of OCD; and being free of pharmacotherapy for at least 8 weeks before baseline (13 of the 27 OCD patients were drug-naive). Patients who presented with comorbid Axis I psychiatric disorders and a history of neurologic disorders were excluded. Two OCD patients who fulfilled inclusion criteria refused to participate in the MRI scanning. They were not counted within the OCD sample total of 27. Control participants were recruited through local print advertising. Inclusion criteria for the healthy controls were: age between 18 and 54; no less than 9 years in education; no DSM-IV Axis I diagnosis; and absence of a history of neurologic disorders.
A trained psychiatrist interviewed all participants with the Mini-International Neuropsychiatric Interview (M.I.N.I.) for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 1994) Axis I mental disorders. The obsessive-compulsive symptoms of each participant were assessed using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). We applied the Hamilton Anxiety Rating Scale (HAMA, 14 items) and Hamilton Depression Rating Scale (HAMD, 24 items) to measure participants' anxiety and depression symptoms respectively.
There were no significant differences between the 27 patients and the 23 controls in age (t = −1.62, df = 48, p = 0.11), gender (χ2 = 0.03, df = 1, p = 0.87) or education (t = −0.62, df = 48, p = 0.52). OCD patients showed higher mean HAMA scores (t = 12.13, df = 48, p<0.001) and mean HAMD scores (t = 9.00, df = 48, p<0.001) than did the healthy controls (Table 1). There were no significant differences between the 13 drug-naive and 14 previously medicated OCD patients in terms of age (t = 0.42, df = 25, p = 0.68), gender (χ2 = 0.22, df = 1, p = 0.88), education (t = −0.52, df = 25, p = 0.61), age at onset (t = 0.93, df = 25, p = 0.36), illness duration (t = −0.53, df = 25, p = 0.61), mean Y-BOCS scores (t = 0.31, df = 25, p = 0.76), mean HAMA scores (t = 0.79, df = 25, p = 0.44) or mean HAMD scores (t = 1.35, df = 25, p = 0.19) at baseline (Table 1).
After receiving clinical feature measurements and DTI scans at baseline, 15 of the 27 OCD patients agreed to accept SSRI treatment only (6 of 15 OCD patients were drug-naive). The decision as to the specific SSRI drug to be used was made by psychiatrists on an individual basis, according to the needs of the patient. SSRI medication included fluvoxamine, 6 patients; fluoxetine 4; sertraline 3; and paroxetine, 2. Medium doses of SSRIs were used within the study in order to balance the effect of medication and potential side effects. Fluvoxamine and sertraline treatments were started at the dose of 50 mg once daily and increased to 150 mg once daily across a period of 6 weeks in 50 mg increments. The maximum dose of 150 mg daily was maintained until the end of the 12-week pharmacotherapy. Fluoxetine and paroxetine treatments were started at 20 mg/day and increased to 40 mg/day across a period of 4 weeks by 20 mg increments. The maximum dose of 40 mg/day was maintained until the end of the 12-week pharmacotherapy. We used the Asberg Rating Scale for Side Effects (SERS) to assess the side effects every 4 weeks. None of the patients dropped out or experienced severe side effects during SSRI treatment.
We scanned OCD patients for DTI data before and after 12-week SSRI treatments. Healthy controls were scanned according to the same time frame as the patients at baseline. All data were acquired using a 1.5T magnetic resonance (MR) scanner (General Electric Medical Systems, Milwaukee, WI, USA). Axial T1-weighted imaging was conducted before the DTI scan in order to quickly locate obvious lesions of cerebral parenchyma. A total of 26 DTI volumes were acquired, including 25 volumes applied with diffusion gradient along 25 non-colinear directions (b = 1000 s/mm2), and one B0 volume without applying diffusion gradient (b = 0). For each volume, 24 continuous slices, each 5-mm-thick, were collected on a 24 cm×24 cm field of view, with the following imaging parameters: repetition time (TR) = 9000 ms, echo time (TE) = 105.5 ms, and matrix = 128*128. The acquisition time was 4 min 12 sec for each participant.
We adopted voxel-based analysis (VBA) in our study, which had been frequently used in previous OCD studies –. All data were processed using SPM8 (http://www.fil.ion.ucl.ac.uk/spm/), and FSL (http://www.fmrib.ox.ac.uk/fsl/) on a Linux based platform. The eddy current distortion was first corrected for each participant's DTI volume using the “eddycorrect” toolbox in FSL. Then, a brain mask, which separated brain and non-brain regions, was calculated from the B0 volume using the BET toolbox (FSL). Restricted within this mask, a diffusion tensor was fitted for each voxel in the brain image space using FSL's DTIFit. FA, AD, RD and MD maps were subsequently calculated.
Next, maps from the control group (23 participants) and patient group before medication (27 participants) were normalized to a B0-template for further statistical testing following a three-step procedure. An optimal method  was used, which is able to more closely match the subjects under investigation and the specific MRI acquisition setting in this study. Initially, a participant-specific B0 template was built with the data from the 23 controls. Each B0 volume was normalized to the SPM EPI template using SPM8's nonlinear coregistration method, with a reslicing resolution of 2×2×2 mm3. These normalized B0 volumes were then averaged and smoothed with a 6-mm FWHM Gaussian kernel to yield the B0 template. Thus the MRI acquisition setting of the resulting B0 template is the same as those data of each subject. Secondly, all original B0 volumes were again normalized to this B0 template, and the resulting transformation parameters applied to their corresponding FA, AD, RD and MD maps. Finally, following a popularly used schema - described in a previous study with OCD patients  - we smoothed all the transformed parameter maps with a 6-mm FWHM Gaussian kernel, ready for further statistical testing. In addition, because the study was focused on white matter abnormality of OCD patients, a white matter mask was created to restrict the search volume for statistics. We first generated a probabilistic tissue map of white matter from the template's B0 image using a tool incorporated in SPM, called “segment”. As the voxel intensity of the probabilistic map ranged from 0.0 to 1.0, we used 0.6 as a threshold to yield this binary white matter mask. The value 0.6 means that the probability of a voxel belonging to white matter is 60%, which we believe is an appropriate threshold to create the binary mask.
To compare the DTI-derived parameters of the patients before and after medication, FA, MD, AD and RD maps from the 15 patients after medication were also normalized to the standard space. To minimize the normalization error, each B0 volume of the post-medication patients was first coregisted to its corresponding B0 volume - collected from the same patient before medication - with the resulting transformation applied to its corresponding FA, AD, RD and MD maps. Then the transformation from patients' B0 volumes before medication to B0 template were applied to these coregisted parameter maps to bring them into the final B0-template space. Finally, a 6-mm FWHM Gaussian smoothing was performed on these normalized parameter maps.
We performed a whole-brain voxel-based analysis using the normalized and smoothed FA, AD, RD and MD maps for a 2-sample group t-test, comparing the 23 control participants and 27 patients before medication. Voxels of T>2.674 (p<0.001, uncorrected, cluster size>10 voxels; 2-tailed) were considered as indicating significant difference between the patient and control groups. This P value has been commonly used in previous DTI-based OCD studies , . The white matter mask was used to confine the statistic only in the white matter region. Averaged maps were created from the normalized FA, AD, RD and MD data from all 50 participants, respectively. Then the corresponding t-test results were superimposed onto the averaged maps, using xjview (http://www.alivelearn.net/xjview8).
The mean FA values in regions which previously showed significant FA difference were calculated for control participants, patients before and patients after medication using the normalized and smoothed FA maps. Similar calculations were also made for AD, RD and MD. The values of these parameters were then correlated to the clinical scores using Pearson's partial correlation analyses, adjusted with age as a controlling factor. A General Linear Model repeated-measure analysis of covariance (ANOVA) was used in the analysis of each DTI-derived parameter before and after treatment. Pre and post-treatment and brain regions with abnormal DTI-derived parameters were set as within-subject factors. ANOVAs with least significant difference (LSD) post hoc tests were used to compare regional DTI-derived parameter changes before and after treatment in OCD patients. Independent t-tests were employed in the analyses of group differences in demographic variables between OCD patients and normal controls, and in demographic and clinical features between drug-naive and previously medicated OCD patients. Paired t-tests were used to compare clinical variables before and after treatment in OCD patients. The tests were two-tailed and the threshold of statistical significance was set at p<0.05.
The results indicate significantly decreased FA in patients compared with healthy controls in the left medial superior frontal gyrus, temporo-parietal lobe and middle occipital gyrus and around the left striatum white matter. Significantly higher RD in patients was shown in the same regions of the left medial superior frontal gyrus, temporal lobe, occipital lobe and striatum that investigated decreased FA. Three other brain areas - the left insula, right frontal lobe and midbrain - demonstrated increased RD and normal FA. Significantly higher AD in patients compared with healthy controls was observed only in the right frontal lobe, where RD was found to be higher while FA was normal. Accompanied by increased RD, there is significantly increased MD in OCD patients compared with healthy controls in the same brain areas of left medial superior frontal gyrus, temporal lobe, occipital lobe, insula and right frontal lobe and midbrain. These regions are illustrated in Figure 1. Montreal Neurological Institute (MNI) coordinates and cluster sizes of the findings are shown in Table 2. Significantly higher FA and lower RD, AD and MD were not shown in any part of the brain white matter in OCD patients compared with healthy subjects.
To compare DTI-derived parameters of patients with and without a history of medication, mean FA, RD, AD and MD values were extracted in regions where significant differences had been found previously between the patient and healthy groups. We found no significant group difference in terms of mean FA, RD, AD and MD values (Table 3).
The total Y-BOCS scores (r = 0.40, df = 24, p = 0.04) and compulsive subscale scores (r = 0.50, df = 24, p = 0.01) were positively correlated with FA in the left striatum. None of the diffusion multi-parameters correlated significantly with HAMA, HAMD, age at onset or illness duration.
After 12 weeks of SSRI treatment, mean Y-BOCS scores, mean HAMA scores and mean HAMD scores in OCD patients were 9.9 (SD = 3.2), 6.4 (SD = 3.9) and 5.5 (SD = 2.6) respectively. This demonstrates significant improvements of 54% (SD = 16%) (t = 9.31, df = 14, p<0.001), 50% (32%) (t = 5.85, df = 14, p<0.001) and 45% (SD = 28%) (t = 4.34, df = 14, p = 0.001) respectively.
To evaluate DTI-derived parameter changes in patients before and after 12-week SSRI treatment, mean FA, RD, AD and MD values were extracted in regions where significant differences had previously been found between the patient and healthy groups. The effect of pre and post-treatment in brain regions with abnormal RD values was found to be statistically significant (F = 7.079, df = 1,14, p = 0.019). There was a significant pre and post-treatment × brain regions with abnormal RD values interaction (F = 5.375, df = 4,54, p = 0.001). Although the effect of pre and post-treatment in the brain regions with abnormal MD values was not statistically significant (F = 3.669, df = 1,14, p = 0.076), the pre and post-treatment × brain regions with abnormal MD values interaction was found to be significant (F = 6.869, df = 3,43, p = 0.001). As to the regional differences, decreased RD was observed in the left striatum (baseline = 0.639×10−3 mm2/s (SD = 0.033), follow-up = 0.615×10−3 mm2/s (SD = 0.021), p = 0.026) and right midbrain (baseline = 0.783×10−3 mm2/s (SD = 0.064), follow-up = 0.742×10−3 mm2/s (SD = 0.054), p = 0.044). Decreased MD was also found in the right midbrain (baseline = 0.947×10−3 mm2/s (SD = 0.066), follow-up = 0.900×10−3 mm2/s (SD = 0.053), p = 0.019) (Figure 2). No significant changes in DTI-derived parameters were found in the left medial superior frontal gyrus, temporal lobe, occipital lobe, insula and right frontal lobe (Table S1).
In order to reduce the possibility of potential type I errors caused by multiple comparisons, we analyzed correlations between symptom changes and DTI derived parameters, which were greatly changed before and after treatment. Decreases in Y-BOCS compulsive subscale scores were significantly correlated with the RD (r = −0.71, df = 12, p = 0.01) values in the left striatum, RD (r = −0.57, df = 12, p = 0.03) and MD (r = −0.58, df = 12, p = 0.03) in the right midbrain at baseline. The mean percentage of RD in the left striatum changed by 4% and RD and MD in the right midbrain both changed by 5%. However, no significant correlations were found either between percentage changes in clinical symptoms and percentage changes in DTI-derived parameters, or between baseline clinical symptoms and percentage changes in DTI-derived parameters.
This is the first DTI study using both multiple parameters and unmedicated OCD patients. This study was therefore designed to be exploratory, using a whole-brain analysis to provide a broad perspective of the pathology found in this patient sample. Two main findings emerged from this study. First, OCD patients demonstrated abnormalities of white matter microstructure, particularly in terms of myelin integrity in multiple sites of the fronto-striato-thalamo-cortical loop. Second, these abnormalities were not a result of previous medication use. Indeed, there are indications that some abnormalities could be partly reversed by SSRI treatment. The interesting findings emerging from this study contribute to the identification of regions of interest relevant to OCD research. At the same time, the data indicates possible regions of focus (e.g. myelination integrity), which may be relevant to ongoing research.
In the present study, abnormal DTI-derived parameters in OCD patients were observed in the white matter including the left medial superior frontal gyrus, temporo-parietal lobe, occipital lobe, insula, right frontal lobe and midbrain and white matter around the left striatum. These structures are located within important brain regions relevant to the pathophysiology of OCD, and indicate abnormalities primarily in the fronto-striato-thalamo-cortical loop. Baseline DTI-derived parameters did not differ between patients with and without medication history.
The prefrontal cortex is primarily involved in cognitive function and emotional information processing in human beings. Both structural and functional imaging studies have supported the existence of abnormalities within the prefrontal cortex, particularly the orbitofrontal cortex, in OCD patients , , . However, two studies reported higher FA and ADC in the medial frontal region , , which is inconsistent with our findings. In the study of Menzies et al. , 23 of the 30 OCD patients had been prescribed the SSRIs, clomipramine and quetiapine. In another study, 2 of 15 OCD patients had comorbid mood disorders and all patients were taking drug treatments for OCD . Yoo et al. have noted in their study that white matter alterations may be partly reversible with citalopram treatment . Therefore, differences in the patient sample may account in part for this inconsistency.
More and more evidence demonstrates that other cortical structures, beside the frontal lobe, participate in the frontal-subcortical circuit . The temporo-parietal junction is a complex sensory cortical area, which is involved in perception and awareness. The fusiform gyrus is thought to be an occipito-temporal gyrus. The fusiform gyrus and the occipital lobe are involved in visual processing, face and body recognition, and word identification. Koprivova et al.  found total white matter volume reduction, with marked reduction particularly in the right temporo-parieto-occipital and left middle temporal gray matter in OCD patients. Furthermore, functional magnetic resonance imaging studies have shown abnormalities in the temporal lobe, parietal lobe and occipito-temporal region , . Similar findings have been reported by Szeszko et al.  and Menzies et al. , suggesting that OCD patients possess lower FA in the bilateral parietal and left occipital lobe. No other DTI studies have reported temporal lobe abnormalities in OCD. The insular has several functions, including interoceptive awareness, motor control, homeostasis and emotional functioning. These functions are all related to the symptoms of OCD. Pujol et al.  reported that their sample of 72 OCD patients demonstrated reduced gray matter volume in the medial frontal gyrus, the medial orbitofrontal cortex and the left insulo-opercular region. One PET study indicated a reduction of serotonin transporter binding in the insular cortex in OCD patients . Our study also found that myelin integrity was damaged in the insular cortex in OCD subjects.
The striatum forms a key region within the subcortical structures involved in the pathophysiology of OCD, and is mainly involved in the planning and modulation of movement pathways. In contrast to our study, two studies have shown significantly higher FA in the internal capsule and white matter in the area superolateral to the right caudate among OCD patients , . The small sample size of these two studies may explain their inconsistency with the results of our study. We also found that FA variables were positively correlated with the severity of compulsive symptoms in the left striatum. Ha et al.  also showed a positive correlation between the Y-BOCS obsessive subscale scores and mean FA values, with the suggestion that this relationship emerges as a compensatory mechanism for neuronal alternations in the anterior cingulate. A further two MRI studies have reported a relationship between striatum volumes and severity of OCD symptoms , . Our results support the proposal that the striatum may be involved in the compulsive symptoms of OCD.
The neurons of the raphe nuclei are distributed along the brainstem and midbrain and are closely related with the serotonin system. Metabolic imaging studies including PET and SPECT have shown decreased serotonin transporter availability in the midbrain and brainstem of OCD patients –. In our study, abnormal white matter microstructure was found in the right midbrain of OCD patients as compared to healthy controls. No other DTI studies have found midbrain abnormalities in OCD. Further studies should be undertaken to investigate the relationship between myelin integrity abnormalities and the serotonin system in OCD patients.
The pathophysiological processes of decreased FA and/or increased MD in OCD patients are indicative of white matter microstructural abnormalities. Higher RD in combination with no change in AD among OCD patients was found in the left medial superior frontal gyrus, temporo-parietal lobe, occipital lobe, striatum, insula and right midbrain, further suggesting that disruptions of myelin integrity contributed to the white matter abnormalities in these regions. This finding is supported by recent genetic studies. There was biased transmission of polymorphisms in the genes involved in myelination in OCD, such as myelin oligodendrocyte glycoprotein (MOG)  and oligodendrocyte lineage transcription factor 2 (OLG2) . Atmaca et al. provided further evidence that the MOG G511C (Val142Leu) polymorphism might be associated with changes in the total white matter volume of OCD patients . The results of these studies support the existence of structural abnormalities of myelin in OCD. We noticed higher AD along with higher RD and MD, and normal FA in the right frontal lobe, which suggests a pattern of both myelination and axonal deficits. A possible explanation is that axial diffusivity occurs as an effective compensatory response when the myelin integrity is impaired.
We also found that abnormal myelin integrity in the left striatum and right midbrain of OCD patients was reversible by 12-week SSRI therapy. Several imaging studies support the finding that abnormalities of frontal-subcortical circuits in OCD patients are partly improved after treatment –. In particular, decreased activation within the left putamen  and increased dysfunctional availability of serotonin transporter in the midbrain  were found after medication in two studies. Yoo et al. further identified that the white matter changes in the FA variable were partly reversible in the right posterior thalamic radiation after 12 weeks of citalopram treatment in OCD patients . There is no direct study exploring the potential pharmacological roles of SSRI on myelination. However, SSRIs are considered to have the effect of neuroprotection and promote activation of Brain Derived Neurotrophic Factor (BDNF) . Xiao et al. proved that BDNF could directly effect oligodendrocytes and increase central nervous system myelination . Interestingly, although we did not find correlations between changes in DTI-derived values and clinical symptoms, DTI-derived parameters before SSRI treatment were significantly correlated with changes in compulsive symptoms. Our findings suggest that baseline DTI-derived parameters in several regions including the left striatum, right frontal lobe and midbrain may be related to the clinical efficacy of SSRI.
Please note although the statistics conducted in this study was uncorrected using a cluster of 10 voxels, we used a cruel p-value threshold of <0.001 to indicate statistical confidence. The use of a small cluster size is in part due to the quality of DTI data collected within this preliminary study. Further research based on this preliminary study and using DTI data of improved image quality, should be driven by carefully designed hypotheses with more rigorous statistical standards.
Several other limitations also exist in the present study. One problem for voxel-based analysis (VBA) is related to multiple comparisons and, therefore, the potential for type I error. To limit the impact of this on the final results, we used RD, AD and MD as complementary measures to the FA result. Another major shortcoming is that VBA is unable to directly provide indications of abnormal connectivity between anatomical structures. Fiber tracking techniques may present an appropriate option to deal with this problem, and will form an aspect of future work following this paper. Slight differences among the four SSRI drugs used in the present study should be considered, although they are all variations of SSRIs and share common pharmacological mechanisms. There is a possibility that changes in DTI-derived parameters in several brain regions before and after 12-week SSRI treatment were related to the passage of time. Further studies employing a “placebo-treated group” would help to tackle this query.
In conclusion, our preliminary findings suggest that in OCD abnormalities of white matter microstructure, particularly in terms of myelin integrity, primarily affect the fronto-striato-thalamo-cortical circuit, independent of previous medication history. These abnormalities attest to the role of white matter in the pathophysiology of OCD. Some abnormalities may be partly reversed by SSRI treatment.
Regional differences in FA, RD, AD and MD before and after treatment in OCD patients.
Click here for additional data file (pone.0035889.s001.doc)
Competing Interests: The authors have declared that no competing interests exist.
Funding: The study was supported by the Joint Key Project of National High Technology Research and Development Program of China (863 Program) (No: 2007AA02Z420), Natural Science Foundation of Shanghai Jiao Tong University School of Medicine, China (No.09XJ21023), Shanghai Municipal Health Bureau Foundation, China (2010Y028), a grant from Shanghai Commission of Science and Technology (No. 10440710200), and two grants from the East China Normal University School Psychology and Cognitive Science. No additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
We thank the staff in Nottingham Institute of Mental Health, University of Nottingham for their help.
|1.||Weissman MM,Bland RC,Canino GJ,Greenwald S,Hwu HG,et al. Year: 1994The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group.J Clin Psychiatry55 Suppl510|
|2.||Koran LM,Thienemann ML,Davenport R. Year: 1996Quality of life for patients with obsessive-compulsive disorder.Am J Psychiatry1537837888633690|
|3.||Rotge JY,Guehl D,Dilharreguy B,Tignol J,Bioulac B,et al. Year: 2009Meta-analysis of brain volume changes in obsessive-compulsive disorder.Biol Psychiatry65758318718575|
|4.||Whiteside SP,Port JD,Abramowitz JS. Year: 2004A meta-analysis of functional neuroimaging in obsessive-compulsive disorder.Psychiatry Res132697915546704|
|5.||Basser PJ,Mattiello J,LeBihan D. Year: 1994MR diffusion tensor spectroscopy and imaging.Biophys J662592678130344|
|6.||Menzies L,Williams GB,Chamberlain SR,Ooi C,Fineberg N,et al. Year: 2008White matter abnormalities in patients with obsessive-compulsive disorder and their first-degree relatives.Am J Psychiatry1651308131518519525|
|7.||Nakamae T,Narumoto J,Shibata K,Matsumoto R,Kitabayashi Y,et al. Year: 2008Alteration of fractional anisotropy and apparent diffusion coefficient in obsessive-compulsive disorder: a diffusion tensor imaging study.Prog Neuropsychopharmacol Biol Psychiatry321221122618442878|
|8.||Szeszko PR,Ardekani BA,Ashtari M,Malhotra AK,Robinson DG,et al. Year: 2005White matter abnormalities in obsessive-compulsive disorder: a diffusion tensor imaging study.Arch Gen Psychiatry6278279015997020|
|9.||Ha TH,Kang DH,Park JS,Jang JH,Jung WH,et al. Year: 2009White matter alterations in male patients with obsessive-compulsive disorder.Neuroreport2073573919322117|
|10.||Garibotto V,Scifo P,Gorini A,Alonso CR,Brambati S,et al. Year: 2010Disorganization of anatomical connectivity in obsessive compulsive disorder: a multi-parameter diffusion tensor imaging study in a subpopulation of patients.Neurobiol Dis3746847619913616|
|11.||Cannistraro PA,Makris N,Howard JD,Wedig MM,Hodge SM,et al. Year: 2007A diffusion tensor imaging study of white matter in obsessive-compulsive disorder.Depress Anxiety2444044617096398|
|12.||Yoo SY,Jang JH,Shin YW,Kim DJ,Park HJ,et al. Year: 2007White matter abnormalities in drug-naive patients with obsessive-compulsive disorder: a diffusion tensor study before and after citalopram treatment.Acta Psychiatr Scand11621121917655563|
|13.||Nakamae T,Narumoto J,Sakai Y,Nishida S,Yamada K,et al. Year: 2011Diffusion tensor imaging and tract-based spatial statistics in obsessive-compulsive disorder.J Psychiatr Res4568769020965515|
|14.||Saito Y,Nobuhara K,Okugawa G,Takase K,Sugimoto T,et al. Year: 2008Corpus callosum in patients with obsessive-compulsive disorder: diffusion-tensor imaging study.Radiology24653654218180336|
|15.||Alexander AL,Lee JE,Lazar M,Field AS. Year: 2007Diffusion tensor imaging of the brain.Neurotherapeutics431632917599699|
|16.||Hasan KM. Year: 2006Diffusion tensor eigenvalues or both mean diffusivity and fractional anisotropy are required in quantitative clinical diffusion tensor MR reports: fractional anisotropy alone is not sufficient.Radiology23961161216641362|
|17.||Song SK,Sun SW,Ju WK,Lin SJ,Cross AH,et al. Year: 2003Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia.Neuroimage201714172214642481|
|18.||Song SK,Yoshino J,Le TQ,Lin SJ,Sun SW,et al. Year: 2005Demyelination increases radial diffusivity in corpus callosum of mouse brain.Neuroimage2613214015862213|
|19.||Tyszka JM,Readhead C,Bearer EL,Pautler RG,Jacobs RE. Year: 2006Statistical diffusion tensor histology reveals regional dysmyelination effects in the shiverer mouse mutant.Neuroimage291058106516213163|
|20.||Ashtari M,Cottone J,Ardekani BA,Cervellione K,Szeszko PR,et al. Year: 2007Disruption of white matter integrity in the inferior longitudinal fasciculus in adolescents with schizophrenia as revealed by fiber tractography.Arch Gen Psychiatry641270128017984396|
|21.||Michael AM,Calhoun VD,Pearlson GD,Baum SA,Caprihan A. Year: 2008Correlations of diffusion tensor imaging values and symptom scores in patients with schizophrenia.Conf Proc IEEE Eng Med Biol Soc20085494549719163961|
|22.||Seal ML,Yucel M,Fornito A,Wood SJ,Harrison BJ,et al. Year: 2008Abnormal white matter microstructure in schizophrenia: a voxelwise analysis of axial and radial diffusivity.Schizophr Res10110611018262770|
|23.||Levitt JJ,Kubicki M,Nestor PG,Ersner-Hershfield H,Westin CF,et al. Year: 2010A diffusion tensor imaging study of the anterior limb of the internal capsule in schizophrenia.Psychiatry Res18414315021055906|
|24.||Whitford TJ,Kubicki M,Schneiderman JS,O'Donnell LJ,King R,et al. Year: 2010Corpus callosum abnormalities and their association with psychotic symptoms in patients with schizophrenia.Biol Psychiatry68707720494336|
|25.||Korgaonkar MS,Grieve SM,Koslow SH,Gabrieli JD,Gordon E,et al. Year: 2011Loss of white matter integrity in major depressive disorder: Evidence using tract-based spatial statistical analysis of diffusion tensor imaging.Hum Brain Mapp322161217121170955|
|26.||Alexander AL,Lee JE,Lazar M,Boudos R,DuBray MB,et al. Year: 2007Diffusion tensor imaging of the corpus callosum in Autism.Neuroimage34617317023185|
|27.||Lee JE,Bigler ED,Alexander AL,Lazar M,DuBray MB,et al. Year: 2007Diffusion tensor imaging of white matter in the superior temporal gyrus and temporal stem in autism.Neurosci Lett42412713217714869|
|28.||Wheeler Kingshott CAM,Cercignani M. Year: 2009About “axial” and “radial” diffusivities.Magn Reson Med611255126019253405|
|29.||Bora E,Harrison BJ,Fornito A,Cocchi L,Pujol J,et al. Year: 2011White matter microstructure in patients with obsessive-compulsive disorder.J Psychiatry Neurosci36424621118658|
|30.||Good CD,Johnsrude IS,Ashburner J,Henson RN,Friston KJ,et al. Year: 2001A voxel-based morphometric study of ageing in 465 normal adult human brains.Neuroimage14213611525331|
|31.||Fan Q,Tan L,You C,Wang J,Ross CA,et al. Year: 2010Increased N-Acetylaspartate/creatine ratio in the medial prefrontal cortex among unmedicated obsessive-compulsive disorder patients.Psychiatry Clin Neurosci6448349020923427|
|32.||Kwon JS,Jang JH,Choi JS,Kang DH. Year: 2009Neuroimaging in obsessive-compulsive disorder.Expert Rev Neurother925526919210199|
|33.||Koprivova J,Horacek J,Tintera J,Prasko J,Raszka M,et al. Year: 2009Medial frontal and dorsal cortical morphometric abnormalities are related to obsessive-compulsive disorder.Neurosci Lett464626619666084|
|34.||Nakao T,Nakagawa A,Nakatani E,Nabeyama M,Sanematsu H,et al. Year: 2009Working memory dysfunction in obsessive-compulsive disorder: a neuropsychological and functional MRI study.J Psychiatr Res4378479119081580|
|35.||Mataix-Cols D,Wooderson S,Lawrence N,Brammer MJ,Speckens A,et al. Year: 2004Distinct neural correlates of washing, checking, and hoarding symptom dimensions in obsessive-compulsive disorder.Arch Gen Psychiatry6156457615184236|
|36.||Pujol J,Soriano-Mas C,Alonso P,Cardoner N,Menchon JM,et al. Year: 2004Mapping structural brain alterations in obsessive-compulsive disorder.Arch Gen Psychiatry6172073015237084|
|37.||Matsumoto R,Ichise M,Ito H,Ando T,Takahashi H,et al. Year: 2010Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: a [11C] DASB PET study.Neuroimage4912112619660554|
|38.||Rosenberg DR,Keshavan MS,O'Hearn KM,Dick EL,Bagwell WW,et al. Year: 1997Frontostriatal measurement in treatment-naive children with obsessive-compulsive disorder.Arch Gen Psychiatry548248309294373|
|39.||Stengler-Wenzke K,Muller U,Angermeyer MC,Sabri O,Hesse S. Year: 2004Reduced serotonin transporter-availability in obsessive-compulsive disorder (OCD).Eur Arch Psychiatry Clin Neurosci25425225515309396|
|40.||Hesse S,Muller U,Lincke T,Barthel H,Villmann T,et al. Year: 2005Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder.Psychiatry Res140637216213689|
|41.||Reimold M,Smolka MN,Zimmer A,Batra A,Knobel A,et al. Year: 2007Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study.J Neural Transm1141603160917713719|
|42.||Zai G,Bezchlibnyk YB,Richter MA,Arnold P,Burroughs E,et al. Year: 2004Myelin oligodendrocyte glycoprotein (MOG) gene is associated with obsessive-compulsive disorder.Am J Med Genet B Neuropsychiatr Genet129B646815274043|
|43.||Stewart SE,Platko J,Fagerness J,Birns J,Jenike E,et al. Year: 2007A genetic family-based association study of OLIG2 in obsessive-compulsive disorder.Arch Gen Psychiatry6420921417283288|
|44.||Atmaca M,Onalan E,Yildirim H,Yuce H,Koc M,et al. Year: 2010The association of myelin oligodendrocyte glycoprotein gene and white matter volume in obsessive-compulsive disorder.J Affect Disord12430931320452030|
|45.||Lazaro L,Bargallo N,Castro-Fornieles J,Falcon C,Andres S,et al. Year: 2009Brain changes in children and adolescents with obsessive-compulsive disorder before and after treatment: a voxel-based morphometric MRI study.Psychiatry Res17214014619321314|
|46.||Jang JH,Kwon JS,Jang DP,Moon WJ,Lee JM,et al. Year: 2006A proton MRSI study of brain N-acetylaspartate level after 12 weeks of citalopram treatment in drug-naive patients with obsessive-compulsive disorder.Am J Psychiatry1631202120716816225|
|47.||Benkelfat C,Nordahl T,Semple W,King A,Murphy D,et al. Year: 1990Local cerebral glucose metabolic rates in obsessive-compulsive disorder: patients treated with clomipramine.Arch Gen Psychiatry478408482393342|
|48.||Saxena S,Brody AL,Ho ML,Alborzian S,Maidment KM,et al. Year: 2002Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression.Arch Gen Psychiatry5925026111879163|
|49.||Lazaro L,Caldu X,Junque C,Bargallo N,Andres S,et al. Year: 2008Cerebral activation in children and adolescents with obsessive-compulsive disorder before and after treatment: a functional MRI study.J Psychiatr Res421051105918261744|
|50.||Nabeyama M,Nakagawa A,Yoshiura T,Nakao T,Nakatani E,et al. Year: 2008Functional MRI study of brain activation alterations in patients with obsessive-compulsive disorder after symptom improvement.Psychiatry Res16323624718667293|
|51.||Stengler-Wenzke K,Müller U,Barthel H,Angermeyer M,Sabri O,et al. Year: 2006Serotonin transporter imaging with [123I]beta-CIT SPECT before and after one year of citalopram treatment of obsessive-compulsive disorder.Neuropsychobiology53404516397403|
|52.||Hunsberger J,Austin DR,Henter ID,Chen G. Year: 2009The neurotrophic and neuroprotective effects of psychotropic agents.Dialogues Clin neurosci1133334819877500|
|53.||Xiao J,Wong AW,Willingham MM,van den Buuse M,Kilpatrick TJ,et al. Year: 2010Brain-derived neurotrophic factor promotes central nervous system myelination via a direct effect upon oligodendrocytes.Neurosignals1818620221242670|
Table 1 The Demographics and Clinical Characteristics of the Baseline Participants.
|Variable||OCD whole group (n = 27)||Drug-naïve OCD subgroup (n = 13)||previously medicated OCD subgroup (n = 14)||Control group (n = 23)|
|Age, mean± SD, y||25.5±7.0||26.1±9.3||24.9±4.1||28.8±7.6|
|Sex, No. M/F||17/10||8/5||9/5||15/8|
|Education, mean ± SD, y||14.0±2.9||13.7±3.1||14.3±2.8||14.6±3.7|
|age at onset, mean ± SD, y||20.4±7.9||21.9±10.1||19.1±5.2||-|
|illness duration, mean ± SD, y||4.8±4.0||4.3±4.6||5.1±3.6||-|
|Total YBOCS score, mean ± SD||22.0±4.9||22.3±4.7||21.7±5.4||0|
|HAMA score, mean ± SD||12.8±4.3||13.5±5.0||12.1±3.6||1.0±1.8|
|HAMD score, mean ± SD||12.4±5.4||13.9±6.1||11.1±4.5||1.4±2.3|
Table 2 Areas of abnormal DTI-derived parameters in 27 patients with obsessive-compulsive disorder and 23 healthy controls before medication.
|Diffusion parameter||Region||Peak coordinates* (x,y,z)||Cluster size||t value|
|FA||Left medial superior frontal gyrus||−10||52||16||29||3.79|
|Left temporo-parietal lobe||−28||−54||22||11||3.91|
|Left middle occipital gyrus||−22||−88||6||31||4.53|
|RD||Left medial superior frontal gyrus||−10||50||16||27||4.50|
|Left temporal lobe||−34||−52||18||29||3.77|
|Left fusiform gyrus, occipital lobe||−26||−74||−6||12||3.59|
|Right frontal lobe||34||14||20||17||4.00|
|AD||Right frontal lobe||34||8||18||71||4.44|
|MD||Left medial superior frontal gyrus||−10||50||16||12||4.13|
|Left temporal lobe||−28||−62||22||25||3.72|
|Left fusiform gyrus, occipital lobe||−26||−76||−8||32||4.30|
|Right frontal lobe||34||14||20||61||4.77|
*peak coordinateds represent the location of the maximum pixel values in standard Montreal Neurological Institute (MNI) space.
df = 48; p<0.001 (uncorrected).
Table 3 Mean FA, RD, AD and MD values between drug-naive and previously medicated OCD patients.
|Diffusion Parameter||Region||Drug-naïve patients (n = 13)||previously medicated patients (n = 14)||t||p|
|FA||Left medial superior frontal gyrus||0.200±0.015||0.195±0.018||0.099||0.922|
|Left temporo-parietal lobe||0.315±0.024||0.305±0.026||0.986||0.334|
|Left middle occipital gyrus||0.250±0.027||0.243±0.042||0.507||0.617|
|RD||Left medial superior frontal gyrus||0.756±0.038||0.744±0.061||0.599||0.554|
|Left temporal lobe||0.660±0.023||0.661±0.051||−0.048||0.962|
|Left fusiform gyrus, occipital lobe||0.652±0.060||0.651±0.059||0.055||0.957|
|Right frontal lobe||0.642±0.038||0.618±0.033||1.730||0.096|
|AD||Right frontal lobe||1.002±0.026||0.986±0.045||1.132||0.268|
|MD||Left medial superior frontal gyrus||0.850±0.034||0.837±0.061||0.666||0.512|
|Left temporal lobe||0.800±0.022||0.800±0.053||−0.014||0.989|
|Left fusiform gyrus, occipital lobe||0.830±0.058||0.820±0.063||0.418||0.680|
|Right frontal lobe||0.759±0.032||0.740±0.030||1.611||0.120|
The units of radial diffusivity (RD), axial diffusivity (AD) and mean diffusivity (MD) is 10−3 mm2/s.
Previous Document: CRISPR interference directs strand specific spacer acquisition.
Next Document: Colorful niches of phytoplankton shaped by the spatial connectivity in a large river ecosystem: a ri...